The Drug Controller General of India (DCGI), along with the Central Drugs Standard Control Organization (CDSCO), is responsible for the approval of licenses of specialized categories of drugs in India, which include blood products, vaccines, IV fluids, and sera. It is the DCGI who lays down the standards and quality of manufacturing, selling, importing, and distributing drugs in India.
For a long time, India has been out of the list for sponsors to invest in conducting clinical trials in India because of lots of uncertainties and losses. But, the changes brought to the guidelines and standards of drug manufacturing, importing, and selling in India by the DCGI recently has helped India again gain momentum for clinical trials. Here are the recent updates by DCGI that have helped attract new clinical trials in the country.
